| Project/Area Number |
15H06289
|
|---|
| Research Category |
Grant-in-Aid for Research Activity Start-up
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Urology
|
|---|
| Research Institution | Mie University |
|---|
Principal Investigator |
KATO Manabu 三重大学, 医学部附属病院, 助教 (60626117)
|
|---|
| Project Period (FY) |
2015-08-28 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥2,600,000 (Direct Cost: ¥2,000,000、Indirect Cost: ¥600,000)
Fiscal Year 2016: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2015: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Keywords | 前立腺癌関連線維芽細胞 / 不均一性 / Heterogeneity / 細胞表面マーカー / 癌関連線維芽細胞 / CD105 / FACS / 去勢抵抗性前立腺癌 / 前立腺癌 / 上皮と間質の相互作用 / 線維芽細胞 |
|---|
| Outline of Final Research Achievements |
We demonstrated that each cancer-associated fibroblsts (CAFs) from different patients expressed diverse cell surface markers such as Stro-1, CD117, CD105 in different ratio. In in vivo, tumor formation assay using one of prostate epithelial cell, 22RV1 mixed with CAFs showed that CD105 neutrilizing reagent suppress this tumor growth dynamically. In addition, 22RV1 had property to change in castration-resistant prostate cancer treated with anti-androgen drug, and made tumor once they cultured in vivo with CAFs. CD105 neutralizing reagent could suppress these tumor also. It seemed that manuplating cell surface markers on CAFs or epithelial cells might be basic strategy to treat cancer assosiated fibroblast, in tumor microenvironment, thus could be treatment for prostate cancer.
|
